Table 1.
Demographic and Clinical Characteristics of the Patients Analyzed.
| Characteristics | Study group |
P | |
|---|---|---|---|
| Resistance exercise (n = 94) | Relaxation control (n = 96) | ||
| Age (years) | 55.4 ± 11.6 | 52.3 ± 12.4 | .352 |
| Male gender | 54 (57.4 %) | 51 (53.1 %) | .563 |
| Body weight (kg) | 69.6 ± 14.3 | 71.3 ± 15.4 | .472 |
| BMI | 26.3 ± 4.9 | 25.9 ± 4.4 | .318 |
| Smoking before diagnosis | 30 (31.9 %) | 28 (29.2 %) | .753 |
| Still smoking at baseline | 10 (10.6 %) | 12 (12.5 %) | .821 |
| Tumor diagnosis | |||
| Rectal cancer | 23 (24.5 %) | 20 (20.8 %) | .605 |
| Cholangiocellular cancer | 17 (18.1 %) | 22 (22.9 %) | .474 |
| Colon cancer | 29 (30.8 %) | 24 (25 %) | .419 |
| Gastric cancer | 18 (19.1 %) | 18 (18.8 %) | 1.000 |
| Pancreatic cancer | 7 (7.5 %) | 12 (12.5 %) | .334 |
| Tumor Stage TNM | |||
| II | 19 (20.2 %) | 17 (17.7 %) | .713 |
| III | 49 (52.1 %) | 56 (58.3 %) | .466 |
| IV | 26 (27.7 %) | 23 (24.0 %) | .620 |
| Previous tumor resection | 74 (78.7 %) | 70 (72.9 %) | .399 |
| Time between tumor resection and recruitment (days) | 63.6 ± 18.1 | 55.7 ± 16.3 | .248 |
| Concomitant radiotherapy | 23 (24.5 %) | 15 (15.6 %) | .149 |
| Days since first chemotherapy | 56.3 ±17.6 | 61.4 ± 19.6 | .276 |
| Chemotherapy protocol | |||
| Oxaliplatin + capecitabine | 36 (38.3 %) | 31 (32.3 %) | .448 |
| Fluorouracil + leucovorin | 21 (22.3 %) | 26 (27.1 %) | .503 |
| Oxaliplatin + leucovorin + fluorouracil | 17 (18.1 %) | 23 (23.9 %) | .375 |
| Others | 20 (21.3 %) | 16 (16.7 %) | .462 |
BMI, body mass index.
Values were expressed as n (percentage) or mean ± SD.